<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38966282</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2659-6636</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Season>Jul-Sep</Season></PubDate></JournalIssue><Title>Open respiratory archives</Title><ISOAbbreviation>Open Respir Arch</ISOAbbreviation></Journal><ArticleTitle>Long-Term Patient Symptoms and Quality of Life in Adults After COVID-19: A Real Life Study.</ArticleTitle><Pagination><StartPage>100336</StartPage><MedlinePgn>100336</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100336</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.opresp.2024.100336</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To characterize long-term patient-reported symptoms and quality of life, in adults after COVID-19.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">Cross-sectional study in Cantabria (Northern Spain) including adults with PCR-confirmed SARS-CoV-2 infection (<i>n</i>&#xa0;=&#xa0;694) with a time period between 4.7 and 24 month post-SARS-CoV-2 diagnosis, and their close contacts (<i>n</i>&#xa0;=&#xa0;663) (PCR negative and without suspected infection) obtained from simple random sampling of a total of 47,773 cases and 94,301 close contacts. The ISARIC survey was used as screening tool with self-reported "non-feeling fully recovery (NFFR)" defined as primary outcome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">16.57% (<i>n</i>&#xa0;=&#xa0;115/694) reported NFFR. Most prevalent symptoms were in order of frequency: Fatigue (54.8%); Loss of smell (40.9%); Problems speaking or communicating (29.6%); Loss of taste (28.7%); Confusion/lack of concentration (27.8%); Persistent muscle pain (24.3%) and Shortness of breath/breathlessness (23.5%). When comparing the three ordinal groups (Close contacts, COVID-19 feeling recovered, and COVID-19 NFFR) the prevalence of these symptoms was increasingly higher among each ordinal group (<i>p</i>&#xa0;&lt;&#xa0;0.001). Female gender was significantly associated with NFFR: (adjusted odds ratio (aOR)&#xa0;=&#xa0;1.56); as well as older age: aOR per 10 year increment&#xa0;=&#xa0;1.15. Lastly, they scored on average 9.63 points less in Euroquol.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">More than 15% of patients in our real-life population-based study, reported NFFR, being female sex and older age independent predictors of this condition. Most symptoms in these patients were in accordance with WHO definition of post COVID-19 condition in adults, and were less prevalent in COVID-19 feeling recovered and close contact respectively, with a statistically significant dose-response pattern, and with a large decrease in quality of life according to Euroquol.</AbstractText><CopyrightInformation>&#xa9; 2024 Sociedad Espa&#xf1;ola de Neumolog&#xed;a y Cirug&#xed;a Tor&#xe1;cica (SEPAR). Published by Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perez</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Observatory of Public Health of Cantabria, Santander, Cantabria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santiba&#xf1;ez</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global Health Research Group, Nursing Department, University of Cantabria (UC) - Marquess of Valdecilla Research Institute (IDIVAL), Santander, Cantabria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasines</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Observatory of Public Health of Cantabria, Santander, Cantabria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo</LastName><ForeName>Jose Maria</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Cantabrian Health Service, UC-IDIVAL, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aginagalde-Llorente</LastName><ForeName>Adrian Hugo</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Subdirection of Public Heath of Guipuzcoa, San Sebasti&#xe1;n, Basque Country, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Open Respir Arch</MedlineTA><NlmUniqueID>9918591885806676</NlmUniqueID><ISSNLinking>2659-6636</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="OBJETIVO" NlmCategory="UNASSIGNED">Caracterizar los s&#xed;ntomas y la calidad de vida informados a largo plazo despu&#xe9;s de un episodio agudo de COVID-19.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Estudio transversal en Cantabria (norte de Espa&#xf1;a) que incluye adultos con infecci&#xf3;n por SARS-CoV-2 confirmada por PCR (n&#xa0;=&#xa0;694) tras un periodo entre 4,7 y 24&#xa0;meses desde el diagn&#xf3;stico y sus contactos estrechos (n&#xa0;=&#xa0;663), obtenidos por muestreo aleatorio simple a partir de 47.773 casos y 94.301 contactos. Se utiliz&#xf3; la encuesta ISARIC, estableci&#xe9;ndose como variable resultado principal la respuesta &#xab;no-sentirse completamente recuperado (NSCR)&#xbb;.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">El 16,57% (n&#xa0;=&#xa0;115/694) declararon NSCR. Los s&#xed;ntomas m&#xe1;s prevalentes fueron, por orden de frecuencia: fatiga (54,8%), p&#xe9;rdida del olfato (40,9%), problemas para hablar o comunicarse (29,6%), p&#xe9;rdida del gusto (28,7%), confusi&#xf3;n/falta de concentraci&#xf3;n (27,8%), dolor muscular persistente (24,3%) y dificultad para respirar/falta de aire (23,5%). Al comparar los tres grupos ordinales (contactos estrechos, COVID-19 recuperados y COVID-19 NSCR), la prevalencia de estos s&#xed;ntomas fue mayor en cada grupo (p&#xa0;&lt;&#xa0;0,001). El sexo femenino se asoci&#xf3; significativamente con NSCR: Odds Ratio ajustada (aOR)&#xa0;=&#xa0;1,56), as&#xed; como la edad avanzada: aOR por cada 10 a&#xf1;os&#xa0;=&#xa0;1,15. Por &#xfa;ltimo, obtuvieron en Euroquol una puntuaci&#xf3;n media de 9,63 puntos menos.</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="UNASSIGNED">M&#xe1;s del 15% de los pacientes reportaron NSCR, siendo el sexo femenino y la edad factores predictores independientes. La mayor&#xed;a de los s&#xed;ntomas en estos pacientes coincidieron con los de la definici&#xf3;n de condici&#xf3;n post-COVID-19 de la OMS y fueron menos prevalentes en contactos estrechos y COVID-19 que se sintieron recuperados, con un patr&#xf3;n dosis respuesta, y con una menor calidad de vida seg&#xfa;n Euroquol.</AbstractText><CopyrightInformation>&#xa9; 2024 Sociedad Espa&#xf1;ola de Neumolog&#xed;a y Cirug&#xed;a Tor&#xe1;cica (SEPAR). Published by Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long-Covid</Keyword><Keyword MajorTopicYN="N">Post-Covid sequelae</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">SARS-CoV2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>4</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38966282</ArticleId><ArticleId IdType="pmc">PMC11223110</ArticleId><ArticleId IdType="doi">10.1016/j.opresp.2024.100336</ArticleId><ArticleId IdType="pii">S2659-6636(24)00039-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F., Gemelli against COVID-19 Post-Acute Care Study Group Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE Guidel. [NG188]; 2020. https://www.nice.org.uk/guidance/ng188 [accessed 10.3.20].</Citation></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigrid L., Drake T.M., Pauley E., Jesudason E.C., Olliaro P., Lim W.S., et al. Long Covid in adults discharged from UK hospitals after Covid-19: a prospective multicentre cohort study using the ISARIC WHO clinical characterization protocol. Lancet Reg Health Eur. 2021;8:100186. doi: 10.1016/j.lanepe.2021.100186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100186</ArticleId><ArticleId IdType="pmc">PMC8343377</ArticleId><ArticleId IdType="pubmed">34386785</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi O.L., Hughes S.E., Turner G., Rivera S.C., McMullan C., Chandan J.S., et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114:428&#x2013;442. doi: 10.1177/01410768211032850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. WHO post covid condition. 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 [accessed 6.10.21].</Citation></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226:1593&#x2013;1607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>ISARIC. WHO. ISARIC-4C global. Available from: https://isaric4c.net/outputs/isaric_global/.</Citation></Reference><Reference><Citation>ISARIC. COVID-19 long term follow up study. 2021. Available from: https://isaric.org/research/covid-19-clinical-research-resources/covid-19-long-term-follow-up-study-old/.</Citation></Reference><Reference><Citation>ISARIC. ISARIC global survey. 2021. Available from: https://isaric.org/wp-content/uploads/2020/12/Tier-1-Initial-Follow_up_survey.pdf.</Citation></Reference><Reference><Citation>Herdman M., Gudex C., Lloyd A., Janssen M., Kind P., Parkin D., et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20:1727&#x2013;1736. doi: 10.1007/s11136-011-9903-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-011-9903-x</ArticleId><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>EuroQol Research Foundation. EQ-5D-3L user guide. Available from: https://euroqol.org/publications/user-guides [accessed 1.2.20].</Citation></Reference><Reference><Citation>O&#x2019;Mahoney L.L., Routen A., Gillies C., Ekezie W., Welford A., Zhang A., et al. The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2022;55:101762. doi: 10.1016/j.eclinm.2022.101762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O., Stehlik P., Clark J., Alcorn K., Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. 2023;2:e000385. doi: 10.1136/bmjmed-2022-000385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000385</ArticleId><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumtaz A., Sheikh A.A.E., Khan A.M., Khalid S.N., Khan J., Nasrullah A., et al. COVID-19 vaccine and long COVID: a scoping review. Life (Basel) 2022;12:1066. doi: 10.3390/life12071066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12071066</ArticleId><ArticleId IdType="pmc">PMC9324565</ArticleId><ArticleId IdType="pubmed">35888154</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Catahay J.A., Velasco J.V., Pastrana A., Ver A.T., Pangilinan F.C., et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine. 2022;53:101624. doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente-Gonz&#xe1;lez M., Suarez-Ortiz M., Landete P. Evolution and clinical trend of SARS-CoV-2 variants. Open Respir Arch. 2022;4:100169. doi: 10.1016/j.opresp.2022.100169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.opresp.2022.100169</ArticleId><ArticleId IdType="pmc">PMC8867977</ArticleId><ArticleId IdType="pubmed">37497318</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., Sun A., Ssentongo A.E., Ba D.M., Parsons N., Poudel G.R., et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6:e005427. doi: 10.1136/bmjgh-2021-005427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T., Hittle M., Goodman S.N. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4:e2111417. doi: 10.1001/jamanetworkopen.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Daher A., Balfanz P., Cornelissen C., M&#xfc;ller A., Bergs I., Marx N., et al. Follow up of patients with severe coronavirus disease 2019 (COVID-19): pulmonary and extrapulmonary disease sequelae. Respir Med. 2020;174:106197. doi: 10.1016/j.rmed.2020.106197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2020.106197</ArticleId><ArticleId IdType="pmc">PMC7573668</ArticleId><ArticleId IdType="pubmed">33120193</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., et al. 6-Month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2023;401:e21&#x2013;e33. doi: 10.1016/S0140-6736(23)00810-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00810-3</ArticleId><ArticleId IdType="pmc">PMC10258565</ArticleId><ArticleId IdType="pubmed">37321233</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-P&#xe9;rez O., Merino E., Leon-Ramirez J.M., Andres M., Ramos J.M., Arenas-Jim&#xe9;nez J., et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect. 2021;82:378&#x2013;383. doi: 10.1016/j.jinf.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Taboada M., Moreno E., Cari&#xf1;ena A., Rey T., Pita-Romero R., Leal S., et al. Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients. Br J Anaesth. 2021;126:e110&#x2013;e113. doi: 10.1016/j.bja.2020.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bja.2020.12.007</ArticleId><ArticleId IdType="pmc">PMC7833644</ArticleId><ArticleId IdType="pubmed">33413976</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>